| Project/Area Number |
21591361
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
LEE Myeongjin 神戸大学, 大学院・医学研究科, 非常勤講師 (20273766)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIMURA Noriyuki 神戸大学, 大学院・医学研究科, 准教授 (00322719)
西尾 久英 神戸大学, 医学研究科, 教授 (80189258)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NISHIO Hisahide 神戸大学, 大学院・医学研究科, 教授 (80189258)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 神経芽腫 / 予後決定因子 / Rab15 / 選択的スプライシング / レチノイン酸 / がん幹細胞 / 自然消退 / Rab / 細胞極性 |
|---|
| Research Abstract |
Neuroblastoma is an aggressive solid tumor that accounts for approximately 15% of all cancer-related deaths in children. More than half of high-risk neuroblastoma patients are estimated to experience relapses and their overall survival rates remain less than 40%. Identification of a new prognostic factor is essential to improve the prognosis of neuroblastoma patients. Aberrant alternative splicing is intimately associated with an increasing number of cancers, and its use as a new diagnostic and/or prognostic biomarker has attracted considerable attention. In the present study, we identified four alternatively spliced isoforms of Rab15, originally isolated as a brain-specific Rab protein. Rab15 isoform balance correlated with differentiation of neuroblastoma tumor-initiating cells(TICs) and Rab15 alternative splicing may serve as a biomarker to discriminate TICs from non-TICs in neuroblastoma.
|
